U.S. Markets closed

The Zacks Analyst Blog Highlights: Adobe, Novo Nordisk, Qualcomm, Boeing, and Uber

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

For Immediate Release

Chicago, IL – November 17, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Adobe ADBE, Novo Nordisk NVO, Qualcomm QCOM, Boeing BA and Uber Technologies UBER.

Here are highlights from Tuesday’s Analyst Blog:

Top Research Reports for Adobe, Novo Nordisk and Qualcomm

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Adobe, Novo Nordisk, and Qualcomm. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Adobe have gained +31.9% in the year to date period against the Zacks Computer - Software industry’s gain of +42.1%. The Zacks analyst believes that Adobe is benefiting from strong demand for its cloud products. The company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products are helping it drive top-line growth.

Additionally, rising subscription revenues and solid momentum across the mobile apps remain major positives. Further, growth in emerging markets, robust online video creation demand, strong Acrobat adoption and improving average revenue per user remain tailwinds. However, lower end-market demand and high acquisition expenses remain major overhangs.

(You can read the full research report on Adobe here >>>)

Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+70.1% vs. +20.4%). The Zacks analyst believes that Novo Nordisk’s Ozempic is off to a solid start and the launch of Rybelsus also looks impressive. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Victoza, Ozempic, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs will further boost sales.

However, lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will affect sales. Sales are also being negatively impacted by COVID-19-related stocking, which is a woe.

(You can read the full research report on Novo Nordisk here >>>)

Shares of Qualcomm have gained +10.6% in the year to date period against the Zacks Wireless Equipment industry’s gain of +13.7%. Qualcomm has already reported solid fourth-quarter fiscal 2021 results with record non-GAAP earnings and revenues, driven by the ramp-up in 5G-enabled chips and a surge in demand for essential products and services that are the building blocks for digital transformation in the cloud economy.

The Zacks analyst believes that Qualcomm is likely to benefit from solid 5G traction with greater long-term visibility. It is on track to record solid revenues across RF front-end, IoT, and Automotive as its business continues to diversify. However, high research and development costs are likely to strain its margins. Severe competition from major players, huge concentration risks, and softness in demand from China might impair its growth potential.

(You can read the full research report on Qualcomm here >>>)

Other noteworthy reports we are featuring today include Boeing and Uber Technologies.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research